Published in Can Med Assoc J on February 03, 1979
Nonspecific and selective stimulation of the immune system in the treatment of carcinoma in humans. Can Med Assoc J (1983) 1.39
Cancer immunotherapy. Can Med Assoc J (1980) 0.75
Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst (1957) 10.10
Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol (1976) 4.37
The role of the reticuloendothelial system in the host reaction to neoplasia. Cancer Res (1961) 3.86
Impaired immunologic reactivity and recurrence following cancer surgery. Cancer (1970) 3.77
Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature (1959) 3.67
Active immunotherapy of L1210 leukaemia applied after the graft of tumour cells. Br J Cancer (1969) 2.96
Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery (1970) 2.34
Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma. N Engl J Med (1976) 1.57
Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin. N Engl J Med (1974) 1.48
Immunological effects of BCG in malignant melanoma: two modes of administration compared. Ann Intern Med (1972) 1.43
Chemotherapy, immunocompetence, immunosuppression and prognosis in acute leukemia. N Engl J Med (1971) 1.38
Treatment of malignant ascitic and pleural effusion with Corynebacterium parvum. Br Med J (1978) 1.36
Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study. Br J Cancer (1975) 1.31
Hypersensitivity reactions at tumor sites. Cancer Res (1969) 1.26
Daily intravenous infusions of Corynebacterium parvum in twenty patients with disseminated cancer: a preliminary report of clinical and biologic findings. J Natl Cancer Inst (1975) 1.09
In vitro and in vivo studies with thymosin in cancer patients. Ann N Y Acad Sci (1976) 1.00
Restoration of cellular immune response by levamisole in patients with Hodgkin's disease. Biomedicine (1975) 0.97
Phase I study of corynebacterium parvum in patients with solid tumors. Cancer Chemother Rep (1976) 0.88
Malignant melanoma metastatic to the bladder. Regression following intratumor injection of BCG vaccine. JAMA (1974) 0.87
Immunodeficiency in cancer and the importance of immune evaluation of the cancer patient. Med Clin North Am (1976) 0.87
Tumour regression and survival of patients with disseminated malignant melanoma treated with chemotherapy and specific active immunotherapy. Eur J Cancer (1977) 0.87
In vitro induction of cell-mediated immunity to murine leukemia cells. III. Effect of methanol extraction residue fraction of BCG on the generation of cytotoxic lymphocytes against leukemia. J Natl Cancer Inst (1978) 0.85
Combination chemotherapy plus methanol extracted residue of bacillus Calmette-Guérin or Corynebacterium parvum in stage III lung cancer. Cancer Treat Rep (1978) 0.81
A new type of synthetic peptide library for identifying ligand-binding activity. Nature (1991) 7.81
Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res (1987) 4.44
Macrophage-lymphocyte interaction in the antigen-induced blastogenic response of human peripheral blood leukocytes. J Immunol (1968) 4.25
The transformation of column-purified lymphocytes with nonspecific and specific antigenic stimuli. J Immunol (1968) 4.24
Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis (1983) 3.86
Impaired in vitro lymphocyte transformation in Hodgkin's disease. N Engl J Med (1965) 3.54
The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med (1988) 2.93
Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis (1985) 2.64
The human primary immune response to keyhole limpet haemocyanin: interrelationships of delayed hypersensitivity, antibody response and in vitro blast transformation. Clin Exp Immunol (1970) 2.40
Minority cancer patients and their providers: pain management attitudes and practice. Cancer (2000) 2.13
Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med (1980) 1.91
Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med (1986) 1.86
13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst (1992) 1.81
Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med (1982) 1.79
Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus. Virology (1991) 1.67
Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. J Natl Cancer Inst (1995) 1.67
Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice. J Infect Dis (1984) 1.67
Active immunotherapy with B.C.G. for recurrent malignant melanoma. Lancet (1973) 1.66
Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res (1979) 1.62
A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. Nature (1987) 1.61
Immunoglobulin on tumor cells and tumor-induced lymphocyte blastogenesis in human acute leukemia. N Engl J Med (1973) 1.57
Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med (1984) 1.57
Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med (1987) 1.55
Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol (1986) 1.50
Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin. N Engl J Med (1974) 1.48
Expression of p21ras in fresh primary and metastatic human colorectal tumors. Proc Natl Acad Sci U S A (1985) 1.47
Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis. Cancer Drug Deliv (1983) 1.43
Immunomorphological features of prognostic significance in Dukes' Class B colorectal carcinoma. Cancer Res (1977) 1.40
The C1q binding test for soluble immune complexes: clinical correlations obtained in patients with cancer. J Natl Cancer Inst (1977) 1.40
Cells capable of colony formation in the peripheral blood of man. Science (1971) 1.40
GM-CSF, carboplatin, doxorubicin: a phase I study. Cancer Chemother Pharmacol (1994) 1.38
Chemotherapy, immunocompetence, immunosuppression and prognosis in acute leukemia. N Engl J Med (1971) 1.38
Avicins: triterpenoid saponins from Acacia victoriae (Bentham) induce apoptosis by mitochondrial perturbation. Proc Natl Acad Sci U S A (2001) 1.37
A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol (1988) 1.36
Antigen dose in the human immune response. Dose-relationships in the human immune response to Keyhole limpet hemocyanin. J Lab Clin Med (1971) 1.32
Pulmonary complications of acute leukemia. Cancer (1966) 1.30
Avicins, a family of triterpenoid saponins from Acacia victoriae (Bentham), inhibit activation of nuclear factor-kappaB by inhibiting both its nuclear localization and ability to bind DNA. Proc Natl Acad Sci U S A (2001) 1.30
Immunological characterization of homosexual males. Cancer Res (1983) 1.29
Patient survival after chemotherapy and its relationship to in vitro lymphocyte blastogenesis. Cancer (1971) 1.29
Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med (1991) 1.28
A plant triterpenoid, avicin D, induces autophagy by activation of AMP-activated protein kinase. Cell Death Differ (2007) 1.28
Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol (1993) 1.28
Chemoimmunotherapy of adult acute leukaemia. Prolongation of remission in myeloblastic leukaemia with B.C.G. Lancet (1974) 1.27
Idiopathic production of interleukin-1 in acquired immune deficiency syndrome. J Clin Microbiol (1987) 1.26
Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. Cancer Res (1974) 1.25
Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res (2001) 1.25
Clinical pharmacology of 99mTc-labeled liposomes in patients with cancer. Cancer Res (1984) 1.23
Lymphocyte activation: a rapid test to predict allograft rejection. Nature (1970) 1.22
Inhibition of drug-metabolizing enzymes in the rat after Bacillus Calmette-Guérin treatment. Biochem Pharmacol (1976) 1.21
Human tumor models in the severe combined immune deficient (scid) mouse. Cancer Chemother Pharmacol (1997) 1.20
Amplified and overexpressed epidermal growth factor receptor gene in uncultured primary human breast carcinoma. Cancer Res (1988) 1.19
Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia. Blood (1987) 1.18
Renal cell carcinoma: antitumor effects of leukocyte interferon. Cancer Res (1983) 1.17
A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia. Am J Med (1990) 1.17
Hepatotoxic effects of methotrexate. Cancer (1966) 1.17
Antibodies to human leucocyte interferons in cancer patients. Lancet (1983) 1.17
Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Res (1990) 1.16
Prophylaxis of Candida albicans infection in neutropenic mice with liposome-encapsulated amphotericin B. Antimicrob Agents Chemother (1984) 1.15
The human secondary immune response to Keyhole limpet haemocyanin. Clin Exp Immunol (1972) 1.15
Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood (1983) 1.15
Triterpenoid saponins from Acacia victoriae (Bentham) decrease tumor cell proliferation and induce apoptosis. Cancer Res (2001) 1.14
Sensitivity of multiple myeloma to imexon in the human tumor cloning assay. J Natl Cancer Inst (1994) 1.13
Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro. J Virol (1990) 1.13
Immune reactivity of lymphoid tissues adjacent to carcinoma of the ascending colon. Surg Gynecol Obstet (1974) 1.13
Leukocyte interferon in patients with juvenile laryngeal papillomatosis. Ann Otol Rhinol Laryngol (1982) 1.13
Lymphadenopathy in homosexual men. Morbid anatomy with clinical and immunologic correlations. Am J Clin Pathol (1983) 1.13
In vitro efficacy of anti-HIV immunotoxins targeted by various antibodies to the envelope protein. J Immunol (1991) 1.12
Randomized trial of protected environment--prophylactic antibiotics in 145 adults with acute leukemia. Medicine (Baltimore) (1978) 1.12
Chemotherapy of malignant lymphoma with adriamycin. Cancer Res (1973) 1.11
Expression of the macrophage colony-stimulating factor and its receptor in gynecologic malignancies. Cancer (1991) 1.11
Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. Clin Cancer Res (2000) 1.11
Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients. Cancer Res (1985) 1.10
Inhibition of in vitro lymphocyte transformation during chemotherapy in man. Cancer Res (1967) 1.09
Effects of surgery, anesthesia and intraoperative blood loss on immunocompetence. J Surg Res (1973) 1.09
Avicins, a family of triterpenoid saponins from Acacia victoriae (Bentham), suppress H-ras mutations and aneuploidy in a murine skin carcinogenesis model. Proc Natl Acad Sci U S A (2001) 1.08
Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol (1985) 1.07
Treatment of a presumed case of sympathetic ophthalmia with methotrexate. Arch Ophthalmol (1966) 1.07
The palliative role of hepatic arterial infusion and arterial occlusion in colorectal carcinoma metastatic to the liver. Lancet (1981) 1.06
The inhibition of lymphocyte blastogenesis by L-asparaginase. Blood (1970) 1.06
Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol (1999) 1.05
Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor. J Immunol (1989) 1.05
Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. Cancer Treat Rep (1979) 1.03
Leukocyte-derived interferon (alpha) in human breast carcinoma. The American Cancer Society phase II trial. Ann Intern Med (1982) 1.03
Inhibition of the local inflammatory response in man by antimetabolites. Blood (1966) 1.03
Antigen solubilized from human leukemia: lymphocyte stimulation. Science (1972) 1.03
Elevated serum thymosin alpha 1 levels associated with evidence of immune dysregulation in male homosexuals with a history of infectious diseases or Kaposi's sarcoma. N Engl J Med (1983) 1.03
Immune thrombocytopenia following alpha-interferon therapy in patients with cancer. JAMA (1985) 1.03
Inhibition of E2F-mediated transcription by p202. EMBO J (1996) 1.02
Differential expression of p21ras gene products among histological subtypes of fresh primary human lung tumors. Cancer Res (1986) 1.02